Navigation Links
Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
Date:10/24/2007

SAN DIEGO, Oct. 24 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, announced today that it will report third quarter 2007 financial results on Thursday, November 1, 2007, after the U.S. financial markets close.

Anadys will hold a conference call and webcast to discuss its third quarter financial results and operational highlights and to give an update on its programs on Thursday, November 1, 2007 at 5:00 p.m. Eastern Daylight Time. To access the webcast via the Internet, log on to http://www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 43320108. The webcast and telephone replay will be available through November 15, 2007.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitis C virus (HCV) infection and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel small molecule medicines in the areas of
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
4. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
5. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
6. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
7. Versatile Reporter Vectors for Monitoring Viral Transduction
8. In Vivo Signal Transduction Pathway Reporting Systems
9. Improved Vectors for PathDetect Trans-Reporting Systems
10. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
11. Cis-Reporting System Monitors Intracellular Calcium Mobilization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics, today announced that ... Global Healthcare Conference in Miami, FL at the Loews Miami ... executive officer of Pfenex, will provide an overview ... on March 12th at 9:00 am ET. A live audio webcast ...
(Date:3/2/2015)... Sterlitech is proud to debut its multi-line, ... 2015 AMTA Membrane Technology Conference in Orlando. This ... of engineering and customer feedback, which has resulted in ... applications across an array of disciplines. It is ... needs of researchers and engineers alike and is ideal ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine Inc. ... aware of a fraudulent press release disseminated this morning ... be from Immunovaccine. This press release states that Immunovaccine ... Inc. The press release did not originate from ... contained within the press release. Please note that ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
Breaking Biology Technology:Sterlitech Displays Complete CF042 Membrane Test System 2Immunovaccine Disclaims Hoax Press Release 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... today published analyses of its second-generation map of ... markers than the initial version unveiled in 2005. ... consortium describes how the higher resolution map offers ... common diseases, explore the structure of human genetic ...
... FRANCISCO, Calif., Oct. 17 Monogram,Biosciences, Inc., (Nasdaq: ... on Wednesday, October 24, 2007 at 4:30 p.m. (Eastern ... will be hosted by Mr.,William D. Young, Chairman and ... teleconference, please call (877) 548-7912,or (719) 325-4878 for international ...
... ARNA ) today reported financial results for the ... the third quarter of 2007 were $5.0 million, compared,to ... revenues in the first,nine months of 2007 were $14.8 ... of 2006. Revenues in the first nine months of ...
Cached Biology Technology:Consortium publishes Phase II map of human genetic variation 2Consortium publishes Phase II map of human genetic variation 3Consortium publishes Phase II map of human genetic variation 4Consortium publishes Phase II map of human genetic variation 5Consortium publishes Phase II map of human genetic variation 6Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 7
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to ... biometrics technology is to ensure that an individual is who ... technology may make use of a person,s unique physical characteristics, ...
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... Robert Burns compared his love to a red, red rose, ... rather than being topped by a lovely, fragrant bloom, a ... crowned by a homely second root. , Researchers at the ... plant Arabidopsis thaliana rather than the elegant rose recently determined ...
... University at Buffalo have received a $2.5 million five-year ... dysfunction called "hibernating myocardium" that can cause disabling heart ... a condition in which myocytes (cells in the heart's ... that receive reduced blood flow over an extended period ...
... University of Florida scientists conducting experiments with mice have ... of cells in the eye essential for healthy vision. ... cell layer vital for eyesight called the retinal pigment ... writing in a recent issue of Investigative Ophthalmology & ...
Cached Biology News:Salk scientists get to the root of plant cell fate 2Salk scientists get to the root of plant cell fate 3Reversing 'hibernating' heart muscle focus of UB researchers 2Bone marrow may restore cells lost in vision diseases 2Bone marrow may restore cells lost in vision diseases 3
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
Biology Products: